Algynomics and Ribotech Launch Joint Research on RNA Correction Platform

Combination of RNA Transposase and Lariat mRNA Technologies to Develop Pure RNA Therapeutics
Verification of Genetic Material Capacity and Repeated Administration Potential Beyond Virus Vectors

Algynomics and Ribotech are joining forces for joint research aimed at developing next-generation ribonucleic acid (RNA) correction therapeutics.

Algynomics, a company specializing in the development of RNA-based gene therapeutics, announced on the 30th that it has signed a joint research agreement with Ribotech to initiate the co-development of a next-generation RNA correction platform.

Algonomics company logo image. Algonomics

The core of this collaboration is to integrate Ribotech's "Lariat mRNA platform" technology with Algynomics' "RNA transposase platform." Through this, the two companies plan to expand the potential applications of pure RNA-based therapeutics.

The traditional DNA virus vector approach can continuously produce therapeutic substances in the body, delivering long-term effects with a single administration; however, it has limitations regarding the loading capacity of large genetic material and can cause immunogenicity upon repeated administration. Although pure RNA therapeutics can mitigate such issues, they have the drawback of short persistence in the body.

The two companies plan to combine the advantages of each technology to verify whether it is possible to enhance in vivo expression efficiency and stability in pure RNA form. If the research succeeds, it is expected to overcome the gene of interest (GOI) size limitation of conventional virus vectors, while also enabling repeated and systemic administration.

Through this joint research, both companies aim to validate the synergy and effectiveness of their foundational technologies and to broaden the application scope of RNA correction therapeutics.

This content was produced with the assistance of AI translation services.